A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Project: Research

Project Details

StatusActive
Effective start/end date2/11/23 → 4/10/25

Keywords

  • clinical trial
  • Cystic Fibrosis
  • respiratory diseases